Compare KG & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KG | BNR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Bermuda | China |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.0M | 216.9M |
| IPO Year | N/A | 2020 |
| Metric | KG | BNR |
|---|---|---|
| Price | $10.38 | $41.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.8K | ★ 33.7K |
| Earning Date | 02-15-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 8.50 | N/A |
| Revenue | $26,676,137.00 | ★ $75,749,382.00 |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.08 | ★ N/A |
| Revenue Growth | ★ 1610.20 | 5.56 |
| 52 Week Low | $8.07 | $2.18 |
| 52 Week High | $36.80 | $34.79 |
| Indicator | KG | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 78.16 |
| Support Level | $8.77 | $29.88 |
| Resistance Level | $10.74 | $34.79 |
| Average True Range (ATR) | 0.86 | 3.64 |
| MACD | 0.34 | 1.39 |
| Stochastic Oscillator | 79.96 | 100.00 |
Kestrel Group Ltd is specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.